Antibacterial Oxazolidinones Possessing a Novel C-5 Side Chain. (5R)-trans-3-[3-Fluoro-4- (1-oxotetrahydrothiopyran-4-yl)phenyl]-2- oxooxazolidine-5-carboxylic Acid Amide (PF-00422602), a New Lead Compound
Journal of Medicinal Chemistry2007Vol. 50(24), pp. 5886–5889
Citations Over Time
Toni‐Jo Poel, Richard C. Thomas, Wade J. Adams, Paul A. Aristoff, Michael R. Barbachyn, F Boyer, Joan K. Brieland, Roger J. Brideau, Joanne Brodfuehrer, Alan Brown, Allison L. Choy, Michael Dermyer, Michael Dority, Charles W. Ford, Robert C. Gadwood, Debra Hanna, Hongliang Cai, Michael D. Huband, Christopher J. Huber, Rose Kelly, Jiyoung Kim, Joseph P. Martin, Paul Pagano, Daniel E. Ross, Laura A. Skerlos, Mark C. Sulavik, Tong Zhu, Gary E. Zurenko, J. V. N. Vara Prasad
Abstract
Oxazolidinones possessing a C-5 carboxamide functionality (reverse amides) represent a new series of compounds that block bacterial protein synthesis. These reverse amides also exhibited less potency against monoamine oxidase (MAO) enzymes and thus possess less potential for the side effects associated with MAO inhibition. The title compound (14) showed reduced in vivo myelotoxicity compared to linezolid in a 14-day safety study in rats, potent in vivo efficacy in murine systemic infection models, and excellent pharmacokinetic properties.
Related Papers
- → Tricyclononene carboxamide derivatives as novel anti-HIV-1 agents(2010)20 cited
- → Synthesis and antiproliferative activity of 2-chlorophenyl carboxamide thienopyridines(2016)20 cited
- → Fragment-Based Lead Generation of 5-Phenyl-1H-pyrazole-3-carboxamide Derivatives as Leads for Potent Factor Xia Inhibitors(2018)8 cited
- → Synthesis and SAR studies of a novel class of S1P1 receptor antagonists(2007)14 cited
- → Lead optimization of a pyridine-carboxamide series as DGAT-1 inhibitors(2012)8 cited